SatraGo2 TED Clinical Trial
Patients with Thyroid Eye Disease (closed for recruitment)
We are conducting a clinical trial to evaluate the effects and safety of a product called satralizumab for patients with thyroid eye disease (TED), also known as Graves’ eye disease or Graves’ orbitopathy.
TED is an autoimmune condition where the body mistakenly attacks healthy tissues surrounding the eyes. Symptoms can range from mild to severe including, pain, bulging of the eyes, and double vision. TED is seen in two different phases, an active phase, where the eyes, eyelids, and eye muscles become swollen, eyes become red and bulge, and fatty tissue behind the eyes get larger, and an inactive/chronic phase where symptoms remain stable, but the fatty tissue hardens, leaving scarred eye muscles.
Current treatment for moderate-to-severe active TED include steroids, and/or TEPEZZA (teprotumumab, in the US only), but these treatments may not be effective for all patients, and can cause many adverse effects. The only current treatment option for inactive/chronic TED is surgery. The purpose of this study is to evaluate the safety and efficacy of satralizumab subcutaneous (under the skin) injections in patients with TED compared to sham control.
Learn More
Patients with Thyroid Eye Disease (closed for recruitment)
We are conducting a clinical trial to evaluate the effects and safety of a product called satralizumab for patients with thyroid eye disease (TED), also known as Graves’ eye disease or Graves’ orbitopathy.
TED is an autoimmune condition where the body mistakenly attacks healthy tissues surrounding the eyes. Symptoms can range from mild to severe including, pain, bulging of the eyes, and double vision. TED is seen in two different phases, an active phase, where the eyes, eyelids, and eye muscles become swollen, eyes become red and bulge, and fatty tissue behind the eyes get larger, and an inactive/chronic phase where symptoms remain stable, but the fatty tissue hardens, leaving scarred eye muscles.
Current treatment for moderate-to-severe active TED include steroids, and/or TEPEZZA (teprotumumab, in the US only), but these treatments may not be effective for all patients, and can cause many adverse effects. The only current treatment option for inactive/chronic TED is surgery. The purpose of this study is to evaluate the safety and efficacy of satralizumab subcutaneous (under the skin) injections in patients with TED compared to sham control.
Learn More